Multiplex Analysis of Serum Cytokines in Melanoma Patients Treated with Interferon-α2b
暂无分享,去创建一个
John M. Kirkwood | Anna E. Lokshin | Howard D. Edington | J. Kirkwood | A. Lokshin | E. Gorelik | Z. Yurkovetsky | Adele M. Marrangoni | Elieser Gorelik | Zoya R. Yurkovetsky | Lyudmila Velikokhatnaya | Matthew T. Winans | H. Edington | A. Marrangoni | Lyudmila Velikokhatnaya | M. Winans
[1] D. Morton,et al. Prognostic factors in 1,521 melanoma patients with distant metastases. , 1995, Journal of the American College of Surgeons.
[2] S. Ugurel,et al. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Jeffrey E. Lee,et al. Significance of Plasma Cytokine Levels in Melanoma Patients With Histologically Negative Sentinel Lymph Nodes , 2001, Annals of Surgical Oncology.
[4] A. Ganser,et al. ©1999 Cancer Research Campaign Article no. bjoc.1998.0189 , 2022 .
[5] D. Jukic,et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] F. Aubin,et al. Circulating vascular endothelial growth factor in cutaneous malignant melanoma , 2005, The British journal of dermatology.
[7] J. Manola,et al. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] G. Bianchi‐Scarrǎ,et al. Cytokine expression in human primary and metastatic melanoma cells: analysis in fresh bioptic specimens , 1995, Melanoma research.
[9] P. Ascierto,et al. Prognostic value of serum VEGF in melanoma patients: a pilot study. , 2004, Anticancer research.
[10] J. Becker,et al. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. , 1995, Melanoma research.
[11] C. Soubrane,et al. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study , 2005, Melanoma research.
[12] J. Manola,et al. A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma , 2004, Clinical Cancer Research.
[13] D. Coit,et al. Prognosis of thick cutaneous melanoma. , 1999, Journal of the American College of Surgeons.
[14] M. Colombo,et al. Expression of cytokine genes, including IL‐6, in human malignant melanoma cell lines , 1992, Melanoma research.
[15] S. Tóth,et al. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. , 2000, Cytokine.
[16] V. Sondak,et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] P. Kellokumpu-Lehtinen,et al. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa. , 1996, Immunopharmacology and immunotoxicology.
[18] R. Peek,et al. Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. , 1999, Melanoma research.
[19] V. Kähäri,et al. New prognostic factors and developing therapy of cutaneous melanoma , 2003, Annals of medicine.
[20] E. Tartour,et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. , 1994, British Journal of Cancer.
[21] Jonathan J. Lewis,et al. Sentinel Lymph Node Biopsy in the Management of Patients With Primary Cutaneous Melanoma: Review of a Large Single-Institutional Experience With an Emphasis on Recurrence , 2001, Annals of surgery.
[22] A. Albino,et al. Update of diagnostic and prognostic markers in cutaneous malignant melanoma. , 1999, Dermatologic clinics.
[23] Raymond L. Barnhill,et al. Long-Term Results of a Prospective Surgical Trial Comparing 2 cm vs. 4 cm Excision Margins for 740 Patients With 1–4 mm Melanomas , 2001, Annals of Surgical Oncology.
[24] S. Groshen,et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] P. Quaglino,et al. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course , 2002, Melanoma research.
[26] C. Soubrane,et al. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. , 2002, Cytokines, cellular & molecular therapy.
[27] William L. Bigbee,et al. Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.
[28] J. Gibbs,et al. Risk Factors for Nodal Recurrence After Lymphadenectomy for Melanoma , 2001, Annals of Surgical Oncology.
[29] D. Taub,et al. Human Interferon-inducible Protein 10 Is a Potent Inhibitor of Angiogenesis in Vivo , 1995 .
[30] D. Vignali. Multiplexed particle-based flow cytometric assays. , 2000, Journal of immunological methods.
[31] A. Eggermont. Critical appraisal of IFN-α-based adjuvant therapy in Stage II–III malignant melanoma , 2002 .
[32] J. Sosman,et al. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. , 2002, Cancer.
[33] M. Herlyn,et al. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes , 1994, International journal of cancer.
[34] I. Clemmensen,et al. Angiogenic balance in human melanoma: Expression of VEGF, bFGF, IL‐8, PDGF and angiostatin in relation to vascular density of xenografts in vivo , 2000, International journal of cancer.